N/A
N=67
Acceptability of Less Harmful Alternatives to Cigarettes
Bladder Cancer · Cervical Cancer · Esophageal Cancer · Gastric Cancer · Head and Neck Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00957424 ↗Enrolled (actual)
67
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcome: Primary: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) — 7 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- telephone-based intervention (Behavioral); nicotine replacement therapy (Drug); informational intervention (Other); internet-based intervention (Other); questionnaire administration (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Roswell Park Cancer Institute
- Primary completion
- Aug 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) |
7 | — |
| PRIMARY Number of Participants Willing to Try HRPs |
60 | — |
| PRIMARY Number of Participants That Completed 1-week Trial |
50 | — |
| PRIMARY Number of Participants Willing to Continue With Preferred HRP |
49 | — |
Summary
RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking.
PURPOSE: This clinical trial is studying the acceptability of less harmful alternatives to cigarettes.
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Currently smokes ≥ 10 cigarettes per day
- Not planning to quit smoking in the next 30 days and has not tried to quit in the past 30 days
- Medically eligible to receive nicotine-replacement products, based on the NYS Smokers Quitline eligibility criteria
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Able to read and speak English
- In good general health
- No history of heart attack or stroke in the past 2 weeks
- No history of chest pains in the past month
- No report of physician-diagnosed arrhythmia/irregular heartbeat or use of pacemaker
- No report of physician-diagnosed heart disease/coronary artery disease, uncontrolled hypertension, stomach ulcer, diabetes, depression, or asthma
PRIOR CONCURRENT THERAPY:
- No other concurrent tobacco products or nicotine medications
- No concurrent Zyban, Bupropion, Wellbutrin, Chantix, or other smoking cessation medication
Data sourced from ClinicalTrials.gov (NCT00957424). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.